Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
| Revenue (TTM) | $11.03B |
| Gross Profit (TTM) | $7.36B |
| EBITDA | $4.18B |
| Operating Margin | 33.60% |
| Return on Equity | 17.40% |
| Return on Assets | 10.50% |
| Revenue/Share (TTM) | $31.07 |
| Book Value | $51.34 |
| Price-to-Book | 7.67 |
| Price-to-Sales (TTM) | 12.67 |
| EV/Revenue | 12.16 |
| EV/EBITDA | 31.60 |
| Quarterly Earnings Growth (YoY) | 26.50% |
| Quarterly Revenue Growth (YoY) | 18.50% |
| Shares Outstanding | $358.28M |
| Float | $351.21M |
| % Insiders | 0.51% |
| % Institutions | 89.68% |
Volatility is currently contracting
ISRG's software roadmap is strengthening da Vinci 5, with new features, renewals and recurring service revenues reinforcing its digital ecosystem.
ISRG's US procedure growth slows in Q2, but ACA-related care deferrals may prove temporary as underlying demand and da Vinci 5 adoption remain strong.
Intuitive Surgical is rated a Hold, with a modeled +9.17% upside and a price target of $426.65. ISRG's growth thesis centers on untapped ASC procedure volume, overstated remanufacturing risks, and remanufacturing's role in expanding the installed base. Remanufacturing currently poses a limited threat, with sub-3% penetration and approval for only 4 out of 45+ instruments.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
I keep hitting the buy button on Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction), and the recent drawdown has only made me press it harder.
ISRG's premium valuation faces scrutiny as strong Q2 growth, higher margins and expanding robotic platforms support its 2026 outlook.
Intuitive Surgical's da Vinci 5 is gaining rapid adoption, fueling hospital upgrades as software enhancements build a potential multi-year capital cycle.
Intuitive Surgical (ISRG) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
ISRG is expanding robotic surgery beyond urology as general surgery and newer specialties gain traction, creating fresh avenues for long-term procedure growth.
ISRG pairs durable platform demand and higher margin guidance with caution on softer U.S. procedure growth and deferred care.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ISRG and any ticker you trade — then tracks every position and per-strategy win rate.
